The Super Bowl 2025 witnessed a controversial advertisement from Hims & Hers, a telehealth company that specializes in health and wellness products. The 30-second spot featured various individuals discussing their engagement with mental health services, promoting treatment options for anxiety and depression. However, the advertisement has drawn significant criticism from the pharmaceutical industry, with leaders asserting that it undermines the professionalism of prescription mental health medications. Dr. John Smith, a psychiatrist and board member of the American Psychiatric Association, stated, ‘While mental health awareness is vital, we must acknowledge the importance of traditional medicinal treatments that have undergone rigorous scientific evaluations.’ The ad showcases relatable scenarios, including a conversation between a couple discussing their mental well-being and a woman sharing her journey towards seeking professional help, thereby sparking discussions on the stigma surrounding mental health. Hims & Hers has defended its advertising strategy, emphasizing the need for accessible mental health resources. CEO Andrew Dudum noted, ‘Our mission has always been to erase the stigma and provide innovative solutions for people struggling with their mental health, and we know from feedback that this message resonates.’ The backlash includes concerns over the portrayal of prescription drugs and the implications of encouraging self-diagnosis. Many healthcare providers worry that messages like these could lead individuals away from necessary medical consultations. In an industry already facing scrutiny for its marketing practices, this incident serves as a focal point for ongoing debates about health, policy, and marketing ethics in the context of mental health. Hims & Hers is also noted for its wide-ranging product line, including treatments for hair loss, ED, skincare, and other health concerns, which has contributed to its popularity among different demographics, particularly younger adults.
Hims & Hers Super Bowl Ad Faces Backlash from Drug Industry
